Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03532789
Other study ID # ECKIRB1051203
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date May 14, 2018
Est. completion date October 23, 2019

Study information

Verified date October 2019
Source En Chu Kong Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Overactive bladder is a clinical syndrome characterized by frequency, with or without urge incontinence, urgency, and nocturia, which affect patients' sleeping quality and rehabilitation program progressing. Current treatments include behavioral therapy (eg, life style adjustment, bladder training, pelvic floor muscle therapy) and medication. Antimuscarinic agents is the most common medications prescribed for OAB, but patients often have side effects like dry mouth and constipation. And there were plenty of herbal medicine which are beneficial to urine frequency and voiding dysfunction in ancient Chinese medicine books and records. In human trial, 62 Subjects diagnosed as overactive bladder will be enrolled and treated with Cinnamon patch. After treatment we will estimate the efficacy and record adverse events to conduct statistically analysis.


Description:

Overactive bladder is a clinical syndrome characterized by frequency, with or without urge incontinence, urgency, and nocturia, which affect patients' sleeping quality and rehabilitation program progressing. Current treatments include behavioral therapy (eg, life style adjustment, bladder training, pelvic floor muscle therapy) and medication. Antimuscarinic agents is the most common medications prescribed for OAB, but patients often have side effects like dry mouth and constipation. And there were plenty of herbal medicine which are beneficial to urine frequency and voiding dysfunction in ancient Chinese medicine books and records. In human trial, 62 Subjects diagnosed as overactive bladder will be enrolled and treated with Cinnamon patch. After treatment we will estimate the efficacy and record adverse events to conduct statistically analysis.

The 1st year project: (1) Expect to enroll 62 clinical subjects of OAB. (2) Evaluate subjects 'symptom and proceed patch treatment. (3) Record treatment responses including adverse effect. (4) Conduct statistically analysis.

The 2nd year project: (1) Completing enrollment of 62 clinical subjects of OAB. (2) Finish evaluation and treatment of all subjects. (3) Statistically analysis all collecting data (4) Discuss and analyze the outcome.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date October 23, 2019
Est. primary completion date October 23, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- urgency score of OABSS = 2 or total score of OABSS = 3

Exclusion Criteria:

- suffering from acute urinary tract infection

- recurrent urinary tract infection = 5 times in the last year

- Hematuria or bladder stone disease

- using foley catheter

- Pregnant or breastfeeding women

- Spinal cord injury patients

- Mental illness or substance abuse

- taking medicine for the treatment of overactive bladder within one month

Study Design


Intervention

Drug:
herbal patch
One patch with medicine should be applied to the skin every other day within two weeks
placebo patch
One patch without medicine should be applied to the skin every other day within two weeks

Locations

Country Name City State
Taiwan EnChuKong hospital New Taipei City Sanxia Dist

Sponsors (1)

Lead Sponsor Collaborator
En Chu Kong Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary OABSS Overactive bladder symptom score, questionnaire Change from Baseline OABSS at 2weeks
Secondary PPBC Patient perception of bladder condition, questionnaire Change from Baseline PPBC at 2weeks
Secondary USS Urgency Severity Scale, questionnaire Change from Baseline USS at 2weeks
Secondary TCMBCQ Traditional Chinese Medicine Body Constitution Questionnaire Change from Baseline TCMBCQ at 2weeks
See also
  Status Clinical Trial Phase
Completed NCT02540707 - Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes Phase 4
Not yet recruiting NCT05977634 - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder N/A
Not yet recruiting NCT06438861 - Role of Combination Therapy in Women With Refractory Overactive Bladder N/A
Completed NCT01114412 - Basic Sensations Coming From the Bladder
Recruiting NCT06045728 - Telerehabilitation for Overactive Bladder Syndrome in Obese Women N/A
Recruiting NCT03952299 - Oxybutynin for Post-surgical Bladder Pain and Urgency Phase 3
Active, not recruiting NCT03758235 - Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin Phase 3
Completed NCT01912885 - Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome N/A
Completed NCT04300400 - Treatment of the Overactive Bladder Syndrome: A Delphi Study
Recruiting NCT04982120 - Use of Repris Needle in Bladder Injection N/A
Completed NCT06123364 - Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder N/A
Recruiting NCT06088394 - Effect of Acupuncture Augmented With Pelvic Floor Exercises on Overactive Bladder N/A
Recruiting NCT05221021 - Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome Phase 4
Terminated NCT04256876 - TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) N/A
Not yet recruiting NCT03331081 - Effects of Bladder Training and Pelvic Floor Muscle Training on the Symptomatology of Overactive Bladder Syndrome N/A
Recruiting NCT04873037 - BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder N/A
Completed NCT02024945 - Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome Phase 4
Completed NCT00546637 - Fesoterodine "add-on" Male Overactive Bladder Study Phase 3
Not yet recruiting NCT06143397 - Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis. N/A
Recruiting NCT03044912 - Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan Phase 3